Literature DB >> 12562536

The challenges of conducting clinical endpoint studies.

Jonathan L Isaacsohn1, Tiffany A Khodadad, Catherine Soldano-Noble, Jeffrey D Vest.   

Abstract

In order to evaluate the effects of a particular treatment strategy on mortality and major morbidity within a disease entity, large, multinational, relatively long-term clinical endpoint studies are often conducted. The primary challenge of conducting these studies is to maintain consistency in the interpretation of the clinical endpoints across different geographic areas and over the long time course of the study. The success of a clinical endpoint study depends on understanding the challenges and incorporating the special requirements of these studies into the protocol design and operational procedures throughout the study.

Mesh:

Year:  2003        PMID: 12562536     DOI: 10.1007/s11883-003-0062-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  10 in total

1.  Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.

Authors:  B M Psaty; N S Weiss; C D Furberg; T D Koepsell; D S Siscovick; F R Rosendaal; N L Smith; S R Heckbert; R C Kaplan; D Lin; T R Fleming; E H Wagner
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

Review 2.  Lessons learned from recent cardiovascular clinical trials: Part II.

Authors:  David L DeMets; Robert M Califf
Journal:  Circulation       Date:  2002-08-13       Impact factor: 29.690

3.  New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.

Authors: 
Journal:  Fed Regist       Date:  1992-12-11

Review 4.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

5.  Surrogates, semantics, and sensible public policy.

Authors:  B E Sobel; C D Furberg
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

6.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1996-09-12       Impact factor: 91.245

7.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

Review 8.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

Authors:  R Collins; S MacMahon
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

9.  Experience collecting interim data on mortality: an example from the RALES study.

Authors:  Janet Wittes; Jolie Palensky; Debra Asner; Desmond Julian; Jean-Pierre Boissel; Curt D Furberg; Henri Kulbertus; Stuart Pocock; Barbara Roniker
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

10.  Systematic adjudication of myocardial infarction end-points in an international clinical trial.

Authors:  Kenneth W Mahaffey; Robert A Harrington; Martijn Akkerhuis; Neal S Kleiman; Lisa G Berdan; Brian S Crenshaw; Barbara E Tardiff; Christopher B Granger; Ingrid DeJong; Manju Bhapkar; Petr Widimsky; Ramón Corbalon; Kerry L Lee; Jaap W Deckers; Maarten L Simoons; Eric J Topol; Robert M Califf
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001-07-17
  10 in total
  1 in total

1.  A web-based endpoint adjudication system for interim analyses in clinical trials.

Authors:  Tracy L Nolen; Bill F Dimmick; Luis Ostrosky-Zeichner; Amy S Kendrick; Carole Sable; Angela Ngai; Dennis Wallace
Journal:  Clin Trials       Date:  2009-02       Impact factor: 2.486

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.